Systemic chemotherapy

V. M. Klimek; J. D. Wolchok; P. B. Chapman; A. N. Houghton; W. J. Hwu

Systemic chemotherapy

V. M. Klimek, J. D. Wolchok, P. B. Chapman, A. N. Houghton, W. J. Hwu

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

The main use of systemic chemotherapy in metastatic melanoma remains palliative. Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the standard chemotherapy agent for advanced disease. The combination chemotherapy and biochemotherapy regimens have achieved higher response rates, but have not led to durable remission or improved survival. The field of systemic therapy remains in need of a more effective and less toxic treatment strategy.

Original language	English (US)
Pages (from-to)	451-461
Number of pages	11
Journal	Clinics in Plastic Surgery
Volume	27
Issue number	3
State	Published - 2000

ASJC Scopus subject areas

Surgery

Cite this

@article{ee46399382e144a2b1bb76fbf84e929a,

title = "Systemic chemotherapy",

abstract = "The main use of systemic chemotherapy in metastatic melanoma remains palliative. Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the standard chemotherapy agent for advanced disease. The combination chemotherapy and biochemotherapy regimens have achieved higher response rates, but have not led to durable remission or improved survival. The field of systemic therapy remains in need of a more effective and less toxic treatment strategy.",

author = "Klimek, {V. M.} and Wolchok, {J. D.} and Chapman, {P. B.} and Houghton, {A. N.} and Hwu, {W. J.}",

year = "2000",

language = "English (US)",

volume = "27",

pages = "451--461",

journal = "Clinics in Plastic Surgery",

issn = "0094-1298",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Systemic chemotherapy

AU - Klimek, V. M.

AU - Wolchok, J. D.

AU - Chapman, P. B.

AU - Houghton, A. N.

AU - Hwu, W. J.

PY - 2000

Y1 - 2000

N2 - The main use of systemic chemotherapy in metastatic melanoma remains palliative. Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the standard chemotherapy agent for advanced disease. The combination chemotherapy and biochemotherapy regimens have achieved higher response rates, but have not led to durable remission or improved survival. The field of systemic therapy remains in need of a more effective and less toxic treatment strategy.

AB - The main use of systemic chemotherapy in metastatic melanoma remains palliative. Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the standard chemotherapy agent for advanced disease. The combination chemotherapy and biochemotherapy regimens have achieved higher response rates, but have not led to durable remission or improved survival. The field of systemic therapy remains in need of a more effective and less toxic treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0033885503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033885503&partnerID=8YFLogxK

M3 - Review article

C2 - 10941565

AN - SCOPUS:0033885503

SN - 0094-1298

VL - 27

SP - 451

EP - 461

JO - Clinics in Plastic Surgery

JF - Clinics in Plastic Surgery

IS - 3

ER -

Systemic chemotherapy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this